Da Volterra, as partner and leader of the NOSOBIO Program, receives a significant grant from OSEO-ISI

NOSOBIO

Da Volterra is the leader of a 6-partner Program called NOSOBIO (http://www.nosobio.fr), targeting the prevention, diagnotics and treatment of patients with multiresistant profiles. Together with Genewave, Palumed, Serial Genetics, the AP-HP and the Pasteur Institute, the Program received a 9 M€ funding by OSEO, within the “ISI” line (Strategic Industrial Innovation).
Visit the website of Genewave, one of the partner of Da Volterra in this program :Genewave

Press Release (in French)